EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients

Rachael Gordon iD, Bo Yen iD, Katherine Dewey iD, Ripal Jariwala iD, Jasleen Kukreja iD, Steven Hays iD, Jonathan P Singer iD, Rebecca Florez iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.14402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Rachael Gordon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Triazoles, Antifungal Agents, Invasive Fungal Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive fungal infections can cause serious complications after lung transplant; therefore, prophylaxis with posaconazole is common. The posaconazole delayed‐release (DR) tablet is preferred. Although the package insert states DR tablets cannot be crushed, recent data suggest it is reasonable. We hypothesized that crushed posaconazole DR tablets could reach therapeutic levels in lung transplant recipients.

Methods

A retrospective study of lung transplant recipients between January 2018 and July 2023, who received crushed posaconazole DR for at least 5 days was completed. Posaconazole troughs were evaluated, and differences were compared between subjects who were therapeutic to those who were subtherapeutic. A cost analysis was also performed.

Results

Thirty subjects received crushed posaconazole DR and 50% were therapeutic. The median trough was 1 mg/L for those who were therapeutic and 0.4 mg/L for those who were not ( p < 0.001). The median cumulative dose was 2000 mg, and there were no significant differences in the incidence of diarrhea or tube feeds. More subjects in the therapeutic group were loaded (33% vs. 13%), although this was not statistically significant ( p = 0.39). No subjects had breakthrough aspergillus one month after starting crushed therapy.

Conclusion

Crushed posaconazole DR tablets are a viable and cost savings option, but loading doses and higher maintenance doses may be required to reach therapeutic levels. Those who received loading doses (intravenously or crushed) followed by a daily crushed dose of 400 mg were more likely to be therapeutic. Limitations of our study include that it is single‐center, small in sample size, and retrospective. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationTriazolesAntifungal AgentsInvasive Fungal InfectionsHumansRetrospective StudiesMaleFemaleMiddle AgedDelayed-Action PreparationsTabletsTransplant RecipientsAdultAged

Stichwörter der Autor:innen

lung transplantpharmacokineticsposaconazole

Substanzen

posaconazoleTriazolesAntifungal AgentsDelayed-Action PreparationsTablets

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
  • Department of Surgery, University of California, San Francisco, California, USA.
  • Department of Medicine, University of California, San Francisco, California, USA.

ORCID-Profile: Rachael Gordon, Bo Yen, Katherine Dewey, Ripal Jariwala, Jasleen Kukreja, Steven Hays, Jonathan P Singer, Rebecca Florez

Zitieren

APA

Gordon, R., Yen, B., Dewey, K., Jariwala, R., Kukreja, J., Hays, S., Singer, J. P., & Florez, R. (2025). Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14402

Vancouver

Gordon R, Yen B, Dewey K, Jariwala R, Kukreja J, Hays S, et al. Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14402

BibTeX
@article{Gordon2025,
  author = {Gordon, Rachael and Yen, Bo and Dewey, Katherine and Jariwala, Ripal and Kukreja, Jasleen and Hays, Steven and Singer, Jonathan P and Florez, Rebecca},
  title = {Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.14402}
}
Kostenlos starten →